With the improvement of people's living standard and the increasing demand of nursing care, the development of nursing specialty has a broad prospect. From the beginning of new China's nursing industry, the rapid development of nursing services after the reform and opening up to the major changes brought about by the "healthy China" strategy in the new era, the nursing service mode has been continuously innovated, the nursing specialty has been expanded rapidly, the nursing professional level has been improved significantly, and China's nursing industry has been developing vigorously. It is of great significance to review the 70 years' nursing development process since the founding of new China and summarize the development experience in planning of the development of nursing specialty in the future.

Tic disorder (TD) is a neurodevelopmental disorder. According to the core symptoms,it can be classified as "liver wind","wind syndrome",and "concurrent". The clinical syndrome of TCM is based on wind,and the pathogenesis is based on the liver. However,the clinical symptoms of this disease are relatively complicated. Based on the " manifestation-qi transformation" theory,this study further explores the liver wind,lung wind,heart wind,spleen wind,and kidney wind from the pathological basis of intrinsic wind rash movement and proposes that the liver wind caused by hyperactivity of liver yang is the main cause of intrinsic wind rash movement in TD,and the lung wind caused by lung loss is the main cause. The liver is related to the heart,spleen,and kidney. Together,the five-wind affect the onset,development,and outcome of TD. Based on this understanding of the pathogenesis,it is necessary to identify the specific syndromes of the patients. The five-wind differentiation and treatment system uses the method of calming the liver and dispelling the lungs to treat the root of the internal wind rash movement. Xiaochaihu Decoction,Sangju Decoction,Cang'erzi Powder,and other prescriptions can be used with modification and subtract and use method of controlling heart fire,transporting spleen soil,and nourishing kidney water to treat derived images. Meanwhile,Xieqing Pill,Daochi Powder,Yigong Powder,Erchen Decoction,Liuwei Dihuang Pill,and other prescriptions can be used with modification.

Objective This study aimed to explore the effects of bone morphogenetic protein 2(BMP-2)encapsula-ted in poly(lactic-co-glycolic acid)(PLGA)microcap-sules with different molecular weights on the osteogenic ability of osteoblasts.Methods PLGA microcapsules with different molecular weights(12 000,30 000)encap-sulating BMP-2,were prepared using a dual-channel mi-croinjection pump.The morphology and structure of the microcapsules were characterized by optical microscopy and scanning electron microscopy.The sustained-release performance of the microcapsules was characterized by phosphate buffered saline immersion method.The cell compatibility of the microcapsules was detected by the Calcein-AM/PI stain-ing and CCK-8 method.The chemotactic effect of BMP-2-encapsulated microcapsules on MC3T3-E1 cells after 48 h of treatment was detected by the Transwell assay.The alkaline phosphatase activity assay and Alizarin Red S staining were used to characterize the effect of microcapsules on the osteogenic ability of MC3T3-E1 cells.Results Both types of mi-crocapsules with different molecular weights exhibited smooth surfaces,as well as uniform and good cell compatibility.The chemotactic effect of the 12 000 microcapsules was outstanding.The 30 000 microcapsules had a longer sustained-release time,and the initial burst release was reduced by approximately 25%compared with the 12 000 microcapsules.In addition,30 000 microcapsules performed better in long-term osteogenesis induction than 12 000 microcapsules.Conclu-sion In this study,the release of BMP-2 is regulated by adjusting the molecular weight of PLGA,and the results indi-cate that 30 000 microcapsules can better induce the long-term osteogenic ability of MC3T3-E1 cells.

Objective:To evaluate the efficacy and safety of hypomethylating agents (HMA) in patients with myelodysplastic syndromes (MDS) .Methods:A total of 409 MDS patients from 45 hospitals in Zhejiang province who received at least four consecutive cycles of HMA monotherapy as initial therapy were enrolled to evaluate the efficacy and safety of HMA. Mann-Whitney U or Chi-square tests were used to compare the differences in the clinical data. Logistic regression and Cox regression were used to analyze the factors affecting efficacy and survival. Kaplan-Meier was used for survival analysis. Results:Patients received HMA treatment for a median of 6 cycles (range, 4-25 cycles) . The complete remission (CR) rate was 33.98% and the overall response rate (ORR) was 77.02%. Multivariate analysis revealed that complex karyotype ( P=0.02, OR=0.39, 95% CI 0.18-0.84) was an independent favorable factor for CR rate. TP53 mutation ( P=0.02, OR=0.22, 95% CI 0.06-0.77) was a predictive factor for a higher ORR. The median OS for the HMA-treated patients was 25.67 (95% CI 21.14-30.19) months. HMA response ( P=0.036, HR=0.47, 95% CI 0.23-0.95) was an independent favorable prognostic factor, whereas complex karyotype ( P=0.024, HR=2.14, 95% CI 1.10-4.15) , leukemia transformation ( P<0.001, HR=2.839, 95% CI 1.64-4.92) , and TP53 mutation ( P=0.012, HR=2.19, 95% CI 1.19-4.07) were independent adverse prognostic factors. There was no significant difference in efficacy and survival between the reduced and standard doses of HMA. The CR rate and ORR of MDS patients treated with decitabine and azacitidine were not significantly different. The median OS of patients treated with decitabine was longer compared with that of patients treated with azacitidine (29.53 months vs 20.17 months, P=0.007) . The incidence of bone marrow suppression and pneumonia in the decitabine group was higher compared with that in the azacitidine group. Conclusion:Continuous and regular use of appropriate doses of hypomethylating agents may benefit MDS patients to the greatest extent if it is tolerated.

Enzyme-catalysis self-assembled oligopeptide hydrogel holds great interest in drug delivery, which has merits of biocompatibility, biodegradability and mild gelation conditions. However, its application for protein delivery is greatly limited by inevitable degradation of enzyme on the encapsulated proteins leading to loss of protein activity. Moreover, for the intracellularly acted proteins, cell membrane as a primary barrier hinders the transmembrane delivery of proteins. The internalized proteins also suffer from acidic and enzymatic degradation in endosomes and lysosomes. We herein develop a protease-manipulated hybrid nanogel/nanofiber hydrogel for localized delivery of intracellularly acted proteins. The embedded polymeric nanogels (CytoC/aNGs) preserve activity of cytochrome